Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction... Show more
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TILL | 20.18 | 0.16 | +0.80% |
| Teucrium Agricultural Strategy No K-1 ETF (TILL) | |||
| MINV | 48.94 | 0.39 | +0.80% |
| Matthews Asia Innovators Active ETF (MINV) | |||
| DFCA | 47.74 | -0.04 | -0.08% |
| Dimensional California Municipal Bond ETF (DFCA) | |||
| FSEC | 41.69 | -0.11 | -0.26% |
| Fidelity Investment Grade Securitized ETF (FSEC) | |||
| UUUG | 2.45 | -0.01 | -0.61% |
| Leverage Shares 2X Long UUUU Daily ETF (UUUG) | |||
A.I.dvisor indicates that over the last year, DFTX has been loosely correlated with IDYA. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if DFTX jumps, then IDYA could also see price increases.
| Ticker / NAME | Correlation To DFTX | 1D Price Change % | ||
|---|---|---|---|---|
| DFTX | 100% | -0.53% | ||
| IDYA - DFTX | 40% Loosely correlated | -1.19% | ||
| AVTX - DFTX | 39% Loosely correlated | +0.27% | ||
| KYMR - DFTX | 36% Loosely correlated | -2.48% | ||
| RLAY - DFTX | 35% Loosely correlated | +2.54% | ||
| RYTM - DFTX | 34% Loosely correlated | -0.62% | ||
More | ||||
The Moving Average Convergence Divergence (MACD) for DFTX turned positive on September 28, 2026. Looking at past instances where DFTX's MACD turned positive, the stock continued to rise in 40 of 43 cases over the following month. The odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 53 of 59 cases where DFTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
Following a +3.89% 3-day Advance, the price is estimated to grow further. Considering data from situations where DFTX advanced for three days, in 238 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
DFTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 01, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DFTX as a result. In 80 of 98 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 82%.
DFTX moved below its 50-day moving average on August 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for DFTX crossed bearishly below the 50-day moving average on September 01, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DFTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
The Aroon Indicator for DFTX entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. DFTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 40 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.618) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DFTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.